9 minutes read

China is the country with the largest cervical cancer burden globally — accounting for 23% of global cases [1]. But on gynecological cancer treatment capability, China has built globally distinctive advantages: Peking Union Medical College Hospital’s Gestational Trophoblastic Neoplasm (GTN) Center is the world’s largest GTN treatment institution (1,130 cumulative cases from 1985-2005, complete response rate 80%) [2]; Akeso’s cadonilimab (PD-1/CTLA-4 bispecific antibody) received NMPA approval in 2022 for recurrent cervical cancer — China’s distinctive contribution to global cervical cancer immunotherapy; Fudan Cancer Gynecologic Oncology performs approximately 3,400 surgeries per year, with advanced techniques including da Vinci Xi robot-assisted gynecologic surgery, PARP inhibitor maintenance therapy, and HIPEC for ovarian cancer all mature. Pricing is typically 1/5 to 1/10 of US. This article walks through China’s gynecological cancer treatment capability by cancer type, leading centers, and the practical international patient pathway.

Epidemiological Context of China’s Gynecological Cancers

Cervical cancer [1]:

  • Accounts for 23% of global cervical cancer cases and 16% of deaths
  • 2018: approximately 570,000 new cases and 311,000 deaths
  • Age-standardized incidence rose from 8.41/100K in 1990 to 11.00/100K in 2019
  • January 2023: National Action Plan for Accelerating Elimination of Cervical Cancer (2023-2030) released — localizing WHO “90-70-90” targets

Endometrial cancer: ASIR continued to rise 1990-2021, though still below global average (98th in incidence, 128th in mortality among 185 countries)

Ovarian cancer: approximately 61,100 new cases in 2022; projected incidence/mortality continue to rise through 2040

Practical implication for international patients: cervical cancer is China’s largest gynecological cancer burden — meaning Chinese clinical case volume is enormous and treatment experience is concentrated. Simultaneously, the full-chain technologies — HPV testing, colposcopy, biopsy, radical surgery, brachytherapy, immunotherapy — are all mature in China.

China’s Leading Gynecological Cancer Centers

Fudan University Shanghai Cancer Center Gynecologic Oncology [3]

  • 120 beds
  • Approximately 3,400 surgeries per year (85%+ major surgeries)
  • Admitted to Shanghai’s 13-hospital International Medical Tourism Pilot
  • Top comprehensive capability domestically

Cancer Hospital, Chinese Academy of Medical Sciences (CICAMS) Gynecologic Oncology [4]

  • Established 1958
  • 130 beds, 50,000 outpatients/year, 2,000+ surgeries/year
  • Anchored by the National Cancer Center

Peking Union Medical College Hospital (PUMCH) Obstetrics and Gynecology [2]

  • National Key Academic Discipline
  • Hospital-wide annual surgery volume >73,000
  • China’s largest Gestational Trophoblastic Neoplasm (GTN) Center (1985-2005, 1,130 GTN cases, CR 80.0%)

Sun Yat-sen University Cancer Center Gynecology

  • Guangdong Province Key Specialty
  • Equipped with da Vinci Xi robot
  • Admitted to Guangdong’s 25-hospital International Medical Service Pilot 2026

Zhejiang University School of Medicine Women’s Hospital [5]

  • 1,120 beds
  • Gynecologic Oncology Department established 1972
  • Led drafting of national GTD guidelines, cure rate at “international advanced” level

Beijing Obstetrics and Gynecology Hospital (Capital Medical University)

  • Founded 1959
  • Gynecologic Oncology Department established 1970

Shandong University Qilu Hospital

  • Gynecologic Oncology subspecialty
  • Professor Kong Beihua serves as CSGO (Chinese Society of Gynecologic Oncology) co-chair

Shanghai Renji Hospital

  • Shanghai Municipal Gynecologic Oncology Key Laboratory anchor

China’s Treatment Capability for Four Major Gynecological Cancers

1. Cervical Cancer — China’s Unique Contribution in Immunotherapy

Core treatments [6]:

  • Radical surgery: open / laparoscopic / robot-assisted radical hysterectomy + pelvic lymph node dissection
  • 3D image-guided (MRI/CT) brachytherapy (HDR) — routinely performed at multiple Chinese centers
  • Concurrent chemoradiation (standard: cisplatin + radiation)
  • Immunotherapy: Cadonilimab (Akeso, PD-1/CTLA-4 bispecific antibody) — Chinese domestic
    • June 2022 NMPA approved for r/m cervical cancer 2nd line
    • 2025 expanded to first-line combined with chemotherapy ± bevacizumab
    • This is China’s distinctive contribution to global cervical cancer immunotherapy — the bispecific mechanism may still be effective in patients who failed PD-1 monotherapy
  • Anti-angiogenesis: bevacizumab (NMPA approved)
  • HPV testing and typing: Chinese mainstream reagents can differentiate 14 high-risk subtypes

Practical value for international patients:

  • China has the world’s largest cervical cancer caseload → surgical experience density among the world’s highest
  • Cadonilimab accessible in China — provides a new option for some patients who failed PD-1 in home country

2. Endometrial Cancer — Molecular Classification Now Standard in China

Core treatment:

  • Molecular classification (4 subtypes) written into 2021 China consensus [7]:
    • POLE-mutated (best prognosis)
    • MMR deficient (suitable for immunotherapy)
    • p53-mutated (high risk)
    • NSMP (Chinese cohort 67.6%, higher than Caucasian populations)
  • Radical surgery (open / laparoscopic / robot-assisted) + pelvic/para-aortic lymph node dissection
  • Fertility-sparing treatment: early low-risk patients use progestins + hysteroscopic ablation to preserve fertility
  • Adjuvant chemotherapy (carboplatin + paclitaxel) + radiation
  • Immunotherapy (MMR-deficient type): pembrolizumab / dostarlimab

For international patients: Chinese endometrial cancer molecular classification is now routine — treatment selection based on molecular features rather than traditional histologic grade, aligned with international guidelines.

3. Ovarian Cancer — PARP + HIPEC Comprehensive Treatment

Core treatment:

  • Cytoreductive surgery (CRS): Fudan Cancer, CICAMS, PUMCH, and other centers achieve R0 resection
  • HIPEC (hyperthermic intraperitoneal chemotherapy) [8]:
    • Chinese multi-center study: Stage III ovarian cancer OS 44.5 months vs 32.4 months (significantly better than without HIPEC)
    • Beijing Shijitan, Fudan Zhongshan, West China, SYSUCC, and others have mature programs
  • PARP inhibitor maintenance therapy (see Article 27):
    • Olaparib (Lynparza, AstraZeneca) — NMPA approved
    • Niraparib (Zejula, introduced by Zai Lab) — NMPA approved
    • Fluzoparib (Airuiyi, Hengrui) — domestic PARP, NMPA approved
    • Pamiparib (BeiGene) — domestic PARP, NMPA approved
    • All included in NRDL (National Reimbursement Drug List)
  • Bevacizumab maintenance: NMPA approved
  • Immunotherapy + chemotherapy: select indications
  • BRCA testing + genetic counseling: mature at top Chinese centers

For international patients: Chinese PARP inhibitor accessibility + mature HIPEC implementation + cytoreductive surgery experience — comprehensive treatment level on par with international standards.

4. Gestational Trophoblastic Neoplasm (GTN) — China is World #1

PUMCH Gestational Trophoblastic Neoplasm Center [2]:

  • 1,130 cumulative GTN cases from 1985-2005
  • Complete response rate (CR) 80.0%
  • World’s largest GTN treatment institution

Zhejiang Women’s Hospital [5]:

  • Led drafting of national GTD guidelines
  • Cure rate at “international advanced” level

GTN scope:

  • Hydatidiform mole
  • Invasive mole
  • Choriocarcinoma
  • Placental site trophoblastic tumor (PSTT)

China’s contribution to global GTN treatment:

  • Massive clinical caseload → deepest experience globally
  • Modified 5-FU + actinomycin D (KSM) regimen Chinese-originated — low cost, effective
  • High-risk GTN EMA-CO regimen widely adopted in China
  • Rich experience in fertility-sparing treatment

For international patients: GTN is China’s strongest unique value proposition in gynecological oncology for international patients — patients with limited GTN experience in their home country may find traveling to China is a sensible choice.

Key Technical Capabilities in Gynecological Oncology

Robot-assisted surgery (see Article 25):

  • Da Vinci Xi routinely performed at SYSUCC, Zhejiang Women’s, and other top centers
  • Applications: early cervical cancer radical hysterectomy, complex endometrial cancer, ovarian cancer cytoreductive surgery
  • Robot-assisted vs open / laparoscopic selection requires individualization — after the LACC trial, minimally invasive surgery indications for early cervical cancer have been tightened

3D image-guided brachytherapy:

  • International standard for cervical cancer brachytherapy
  • Widely performed at major Chinese Tier-3A hospitals

Fertility-sparing treatment:

  • Radical trachelectomy
  • Hysteroscopic + progestin protocol for early EC
  • Unilateral adnexectomy for early ovarian cancer

MDT multidisciplinary consultation (see Article 10):

  • Gynecological oncology is a strongly recommended MDT indication in international guidelines

Pricing Comparison

Treatment US China Estimate
Cervical cancer radical surgery + adjuvant radiation ~$30,000–$50,000 Approximately $1,673 (single-center study) [9]
Laparoscopic hysterectomy $11,550–$27,325 (average $19,450) [10] Approximately $4,000–$8,000
Ovarian cancer full treatment (surgery + chemotherapy + maintenance) First year ~$100,000+ [11] Approximately $9,030 (Tianjin 2019 study) [12]
PARP inhibitor maintenance (annual) $10,000–$15,000 Substantially reduced after NMPA + NRDL

Core value: Chinese gynecological cancer treatment all-inclusive costs are approximately 1/5 to 1/10 of US — especially economically meaningful for ovarian cancer patients requiring long-term chemotherapy + maintenance therapy.

Practical International Patient Pathway for Gynecological Cancer Treatment in China

Best-suited international patients for travel to China:

  1. Gestational trophoblastic neoplasm (GTN) patients — PUMCH, Zhejiang Women’s globally leading
  2. Recurrent cervical cancer — cadonilimab China-exclusive
  3. Advanced ovarian cancer requiring comprehensive treatment (CRS + HIPEC + PARP maintenance)
  4. Long home country treatment wait times or unaffordable cost
  5. Fertility-sparing treatment (early-stage patients wishing to preserve fertility)

Typical timeline:

Phase Duration
Pre-travel evaluation + pathology re-reading 4–6 weeks (remote)
Arrival + MDT consultation 1 week
Surgery + post-operative inpatient 1–2 weeks
Adjuvant chemotherapy / radiation (plan-dependent) 4–24 weeks
Early follow-up 1–2 weeks
Maintenance therapy + long-term remote follow-up Plan-dependent

Total time in China: 3–10 weeks (depending on plan complexity; chemo/radiation can be continued back home as appropriate)

Common Questions

Is China’s cervical cancer surgical experience really the world’s largest? Yes — China accounts for 23% of global cervical cancer cases, meaning the world’s largest surgical caseload. Fudan Cancer, CICAMS, PUMCH, SYSUCC, and other centers’ gynecological cancer surgical experience density is among the world’s highest.

How does cadonilimab compare with US Keytruda? Different mechanisms: cadonilimab is a PD-1/CTLA-4 bispecific antibody; Keytruda is a PD-1 monoclonal antibody. In some patients who failed PD-1 monotherapy, the bispecific mechanism may still be effective. For cervical cancer first- and second-line, both are reasonable options — MDT evaluation required.

What’s the unique value of traveling to China for GTN? World’s largest experience — PUMCH’s 1,130 GTN clinical case data; Chinese-originated treatment regimens (such as modified 5-FU+KSM); rich experience in fertility-sparing treatment — young patients wishing to preserve fertility.

Can early ovarian cancer preserve fertility? Depends on specifics — early-stage unilateral adnexal ovarian cancer (Stage IA, low-grade) + young patient with fertility intention may consider fertility-sparing surgery (unilateral adnexectomy). Top Chinese centers have rich experience; similar principles to those discussed in Article 28 on pediatric oncology.

Does HIPEC really work? For advanced ovarian cancer, supported by Chinese multi-center evidence (OS 44.5 vs 32.4 months). Indications require MDT evaluation — not all ovarian cancers are suitable for HIPEC.

How does international insurance reimbursement work for gynecological cancer treatment in China? Most premium international medical insurance plans cover oncology treatment. The key is to confirm policy coverage scope + lifetime cap before traveling.

Can chemotherapy / maintenance therapy be continued in my home country? Surgery + early chemotherapy completed in China; subsequent maintenance chemotherapy / PARP inhibitor can be continued at home — see Article 27 on cross-border use of targeted drugs.

Bottom Line

Core value of gynecological cancer treatment in China:

  • Gestational trophoblastic neoplasm (GTN) world #1 (PUMCH, Zhejiang Women’s)
  • Cadonilimab (PD-1/CTLA-4 bispecific) unique to China — new option for recurrent cervical cancer
  • National Action Plan for Accelerating Elimination of Cervical Cancer + world’s largest surgical caseload
  • Endometrial cancer molecular classification standardized
  • Ovarian cancer PARP + HIPEC + cytoreductive surgery comprehensive treatment internationally synchronized
  • Pricing approximately 1/5 to 1/10 of US

Best-suited international gynecological cancer patients for travel to China:

  • GTN (hydatidiform mole, choriocarcinoma, etc.) — China world #1
  • Recurrent cervical cancer seeking immunotherapy (especially cadonilimab)
  • Advanced ovarian cancer comprehensive treatment
  • Early gynecological cancer wishing for fertility-sparing treatment
  • Unaffordable home country treatment costs

Total time in China: 3–10 weeks (plan-dependent)

If you are a gynecological cancer patient, MedCareInChina matches the most appropriate Chinese gynecological cancer center and treatment plan based on your specific diagnosis (including HPV status, molecular classification, BRCA, etc.).

→ Send your case to hello@medcareinchina.com

See Service & Refund Policy and Medical Disclaimer for service boundaries.

Sources

  1. China cervical cancer epidemiology — 23% of global cases, 16% of deaths; approximately 570,000 new cases and 311,000 deaths in 2018. ASR 1990-2019. Sources: PMC https://pmc.ncbi.nlm.nih.gov/articles/PMC10951371/ ; China CDC Weekly https://weekly.chinacdc.cn/en/article/doi/10.46234/ccdcw2024.040
  2. PUMCH Gestational Trophoblastic Neoplasm Center — 1,130 cumulative GTN cases 1985-2005, CR 80%. Source: PubMed https://pubmed.ncbi.nlm.nih.gov/19874291/
  3. Fudan Cancer Gynecologic Oncology — 120 beds, approximately 3,400 surgeries/year (>85% major). Source: https://clinicsoncall.com/en/clinic/fudan-university-cancer-center/
  4. CICAMS Gynecologic Oncology — Established 1958, 130 beds, 50,000 outpatients/year, 2,000+ surgeries. Source: CICAMS https://www.cicams.ac.cn/dzb/navigation/fu.html
  5. Zhejiang University Women’s Hospital — 1,120 beds, led drafting of national GTD guidelines. Source: https://zju.womanhospital.cn/
  6. Cadonilimab (PD-1/CTLA-4 bispecific) — Akeso, June 2022 NMPA approval for r/m cervical cancer 2nd line, 2025 expanded to 1st line. Source: PMC https://pmc.ncbi.nlm.nih.gov/articles/PMC12003394/
  7. China endometrial cancer molecular classification consensus — 2021, POLE/MMR/p53/NSMP 4-subtype. Source: PubMed https://pubmed.ncbi.nlm.nih.gov/38277742/
  8. Ovarian cancer HIPEC China study — Stage III OS 44.5 vs 32.4 months. Source: Frontiers in Oncology https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1336616/full
  9. China cervical cancer surgery + radiation cost — Single-center study average approximately ¥10,872 (~$1,673). Source: PMC https://pmc.ncbi.nlm.nih.gov/articles/PMC4727512/
  10. US laparoscopic hysterectomy cost — Average $19,450 ($11,550-$27,325). Source: AJOG https://www.ajog.org/article/S0002-9378(24)00846-9/abstract
  11. US ovarian cancer first-year treatment cost — ~$100,000; initiation phase annual can be >$200,000. Source: Resolve Medical Bills and other aggregated data.
  12. China ovarian cancer full-treatment cost — Tianjin 2019 study average approximately $9,030. Source: ATM https://atm.amegroups.org/article/view/99656/html
  13. WHO 90-70-90 + China Action Plan for Accelerating Elimination of Cervical Cancer (2023-2030) — Released January 2023.
  14. International patient visa and access pathway — S2 visa + Tier-3A hospital IMD invitation letter.